ReviewDrug design, development and therapy2015
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
Runzhe Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
13 papers cite it
this papercites it
ReviewDrug design, development and therapy2015
Runzhe Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.